Outcomes with second-line chemotherapy in advanced pancreatic cancers: A retrospective study from a tertiary cancer center in India

Simple item page
dc.contributor.authorRamaswamy, Ananten_US
dc.contributor.authorParthiban, Sangeethaen_US
dc.contributor.authorMalhotra, Mridulen_US
dc.contributor.authorKothari, Rushabhen_US
dc.contributor.authorGoel, Aloken_US
dc.contributor.authorBhargava, Prabhaten_US
dc.contributor.authorSujay, Srinivasen_US
dc.contributor.authorSuyash, Kulkarnien_US
dc.contributor.authorOstwal, Vikasen_US
dc.date.accessioned2020-01-02T06:27:59Z
dc.date.available2020-01-02T06:27:59Z
dc.date.issued2018-04
dc.description.abstractINTRODUCTION: Approximately 40% of patients receiving first-line chemotherapy (CT1) for advanced pancreatic adenocarcinomas (PDACs) receive second-line chemotherapy (CT2). The most appropriate regimen to be used has not been identified, and data regarding CT2 in advanced PDAC from India are scarce. MATERIALS AND METHODS: A retrospective analysis of advanced PDAC patients who were evaluated during the period of August 2013 to August 2016 in the Department of GI medical Oncology, at Tata Memorial Hospital was conducted. Patients with histologically proven PDAC and started on CT2 postprogression or recurrence after CT1 were included for analysis. RESULTS: A total of 237 patients received CT1 in the period of study, of which 76 patients (39.66%) received CT2. The median age of patients was 59.5 years (range: 38–82), majority were male (69.7%), and 14 patients (18.4%) had undergone curative pancreatic resection at baseline. The common regimens used as CT2 were modified 5 fluorouracil/leucovorin/irinotecan (mFOLFIRI) (35.5%), gemcitabine-nab paclitaxel (18.4%), and gemcitabine-erlotinib (11.8%). Common grade 3/4 toxicities noted were fatigue (10.3%), anemia (10.3%), neutropenia (7.4%), and vomiting (7.4%). Dose reductions were required in 32.9% of patients. RR, DCR, median event free survival, and median overall survival were 21.1%, 48.7%, and 5.94 months (95% confidence intervals [CI]: 4.68–7.20) and 8.08 months (95% CI: 7.11–9.07) respectively. CONCLUSIONS: CT2 in advanced PDAC appears feasible in the Indian setting if the patients are appropriately selected and they can be treated with acceptable toxicities and reasonable outcomes.en_US
dc.identifier.affiliationsDepartment of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtraen_US
dc.identifier.citationRamaswamy Anant, Parthiban Sangeetha, Malhotra Mridul, Kothari Rushabh, Goel Alok, Bhargava Prabhat, Sujay Srinivas, Suyash Kulkarni, Ostwal Vikas. Outcomes with second-line chemotherapy in advanced pancreatic cancers: A retrospective study from a tertiary cancer center in India. Indian Journal of Cancer. 2018 Apr; 55(2): 144-147en_US
dc.identifier.issn0019-509X
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/190336
dc.languageenen_US
dc.publisherIndian Cancer Societyen_US
dc.relation.issuenumber2en_US
dc.relation.volume55en_US
dc.source.urihttps://dx.doi.org//10.4103/ijc.IJC_553_17en_US
dc.titleOutcomes with second-line chemotherapy in advanced pancreatic cancers: A retrospective study from a tertiary cancer center in Indiaen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijoc2018v55n2p144.pdf
Size:
451.54 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Cancer